MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3748/wjg.v23.i29.5395

Медицинская библиотека · World journal of gastroenterology · 2017

Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma.

Shen Jie, Wang Li-Feng, Zou Zheng-Yun, Kong Wei-Wei, Yan Jing, Meng Fan-Yan, Chen Fang-Jun, Du Juan, Shao Jie, Xu Qiu-Ping, Ren Hao-Zhen, Li Ru-Tian, Wei Jia, Qian Xiao-Ping, Liu Bao-Rui

Клиническое исследование I фазыСтатьяПеревод в очереди

Аннотация

AIM: To assess the efficacy and safety of a new treatment modality, cellular immune therapy based on personalized peptide vaccination (PPV-DC-CTL) combined with radiotherapy, for treating advanced hepatocellular carcinoma (HCC).

METHODS

A total of nine patients with advanced HCC were enrolled. Multidisciplinary consultation confirmed that all the patients definitely had no opportunity of surgery, because four patients had multiple liver metastases (the number of liver lesions > 3), one patient had liver metastases and portal vein tumor thrombosis, one patient had lung and bone metastases, two patients had liver and lung metastases and one patient had liver metastasis and peritoneal metastasis. Patients with metastasis were treated with precise radiotherapy combined with PPV-DC-CTL.

RESULTS

Following radiotherapy and one to three cycles of PPV-DC-CTL treatment, AFP levels were significantly decreased in six patients and imaging assessment of the lesions showed a partial response (PR) in three patients and stable disease in the other three patients. The response rate was 33% and disease control rate was 66%. This regimen was found to be safe and well tolerated. None of the patients developed liver or kidney side effects. Only one patient developed grade II bone marrow suppression and the remaining patients had no significant hematological side effects.

CONCLUSION

Radiotherapy combined with PPV-DC-CTL provides a new therapeutic strategy for patients with advanced HCC, which is well tolerated, safe, feasible and effective.

Для цитирования: Shen Jie, Wang Li-Feng, Zou Zheng-Yun, Kong Wei-Wei, Yan Jing, Meng Fan-Yan, Chen Fang-Jun, Du Juan, Shao Jie, Xu Qiu-Ping, Ren Hao-Zhen, Li Ru-Tian, Wei Jia, Qian Xiao-Ping, Liu Bao-Rui. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma.. World journal of gastroenterology. 2017. DOI: 10.3748/wjg.v23.i29.5395.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.